Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.640
-0.020 (-1.20%)
At close: Sep 12, 2025, 4:00 PM EDT
1.670
+0.030 (1.83%)
After-hours: Sep 12, 2025, 6:58 PM EDT
Immutep Employees
The last reported number of employees for Immutep was 31.
Employees
31
Change
n/a
Growth
n/a
Revenue / Employee
$106,669
Profits / Employee
-$1,299,251
Market Cap
224.01M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMMP News
- 6 days ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 6 weeks ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 6 weeks ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 3 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 4 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 4 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 5 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire